Full Press Release Details
FDA Grants Breakthrough Therapy Designation And Orphan Drug Designation To PellePharm For Topical Patidegib In Gorlin Syndrome.
BBIO
FDA Grants Breakthrough Therapy Designation And Orphan Drug Designation To PellePharm For Topical Patidegib In Gorlin Syndrome
Key Takeaway: FDA Grants Breakthrough Therapy Designation And Orphan Drug Designation To PellePharm For Topical Patidegib In Gorlin Syndrome
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+41%
120-day peak, hindsight
Typical move
3.6%
average across 13 past catalysts
Cash runway
~30 mo
Minimal dilution risk
Lead asset
acoramidis
Phase 3 · Amyloidosis